Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins
2005
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
2009
Chemotherapy for small cell lung cancer
2003
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
2002
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistance
2004
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles
2007
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients
2008
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
PharmGKB summary
2013
Targeting multidrug resistance in cancer
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Chemotherapy and the war on cancer
2005 Standout
Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center
2000
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus
2007 StandoutNobel
TFOS DEWS II Management and Therapy Report
2017 Standout
Gastric Small Cell Carcinoma Successfully Treated by Surgery and Postoperative Chemotherapy Consisting of Cisplatin and S-1: Report of a Case
2007 StandoutNobel
Evaluation of the antidepressant activity of Moringa oleifera alone and in combination with fluoxetine
2015 Standout
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
Microtubules as a target for anticancer drugs
2004 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Liposomes as nanomedical devices
2015 Standout
Herb-Drug Interactions
2005 Standout
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811
2006
Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer
2002
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
RECIST revisited: A review of validation studies on tumour assessment
2006
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.
1998
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Gemcitabine
1997
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
2008
Small-cell lung cancer
2011
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Novel SN-38–Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor–Secreting Bulky Tumors
2006
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Cardiovascular effects of Danshen
2007 Standout
Enhancement of DNA topoisomerase I inhibitor–induced apoptosis by ursodeoxycholic acid
2006
Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2009
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Combination therapy in combating cancer
2017 Standout
Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non-Small Cell Lung Cancer
2001
Uptake and Intracellular Distribution of Amrubicin, a Novel 9‐Amino‐anthracycline, and Its Active Metabolite Amrubicinol in P388 Murine Leukemia Cells
1999
Pharmacokinetic Interactions of Drugs with St John’s Wort
2004
Synthesis of random copolymer based pH-responsive nanoparticles as drug carriers for cancer therapeutics
2013 StandoutNobel
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature
2005
Works of Y Takada being referenced
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
2003
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
2009
Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC)
1996
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
2007
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
1998
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients
2006
Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients
2005
[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
1996
294 A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis
1997
Randomized phase III trial compared cisplatin and irinotecan (CPT-P) versus cisplatin and vindesine (VDS-P) versus irinotecan alone (CPT) in patients with advanced non-small cell lung cancer (NSCLC) — The final report
2000
55 Phase II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC): A trial of the west Japan lung cancer group
1997
The impact of an independent response evaluation committee (REC) using RECIST guidelines in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan
2004